Vaccine Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Vaccines
GeneThera Releases Results From Initial Animal Tests of E.Coli O157:h7 Vaccine Amid News of Increase of E.Coli Discoveries in Beef Products
December 3rd, 2008
GeneThera, Inc. (Pink Sheets: GTHR), released information about its E.Coli O157:H7 vaccine. The vaccine consists of Live Attenuated Bacterial Vaccine to Reduce or Inhibit Carriage and Shedding of Enterohemorrihagic Escherichia Coli in Cattle. This vaccine was developed for use against Shiga toxin-producing E.Coli (STEC) in cattle. This strategy is to construct mutants that have deletion in the genes responsible for E.Coli O157:H7 toxicity. Along with the mutation to inactivate the Shiga toxin gene, the modified bacteria also carry a mutation that inactivates genes that allows the growth of the E.Coli 0157:H7 in the cow intestine. These modifications will greatly...
Source: Vaccine Weekly (2008-12-03)
|
